David Burns

Special Counsel
Full contact info

Experience

Keros Therapeutics Announces Ex-China Global License Agreement With Takeda

December 3, 2024

Cooley advised Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins, on its exclusive global development and commercialization license agreement with Takeda Pharmaceuticals to advance elritercept.

Read more

Related contacts

Alan W. Tamarelli
Partner, New York
Ryan Sansom
Partner, Boston
Marc Recht
Partner, Boston
David Burns
Special Counsel, Washington, DC
Natasha Kaye
Partner, London
Navya Dasari
Associate, New York
Amanda Pacheco
Associate, Palo Alto
Bartholomäus Regenhardt
Associate, Brussels
Stella Sarma
Special Counsel, Brussels
Jan Lang
Associate, Brussels

Related Practices & Industries

Chimagen Biosciences Announces Sale of CMG1A46 to GSK

October 29, 2024

Cooley advised Chimagen Biosciences, a privately held biotechnology company, on its agreement to sell CMG1A46, a clinical-stage dual CD19 and CD20-targeted T-cell engager (TCE), to GSK, a global biopharma company, for an upfront payment of $300 million, plus success-based development and commercial milestone payments totaling up to $550 million.

Read more

Related contacts

Marya Postner
Partner, Palo Alto
Yiming Liu
Partner in Charge – Shanghai, Shanghai
Zack Gong
Associate, Shanghai
Jenny Ge
Associate, Santa Monica
Monica Xu
Counsel, Shanghai
Natasha Kaye
Partner, London
Christopher Kimball
Partner, Washington, DC
Rama Padmanabhan
Partner, San Diego
Aaron Pomeroy
Partner, Colorado
Jonathan Rivinus
Partner, Colorado
Rachel Thorn
Partner, New York
David Wilson
Partner, London
David Burns
Special Counsel, Washington, DC
Sharon Connaughton
Special Counsel, Washington, DC
Andrew Epstein
Special Counsel, Seattle
Bin Wang
Special Counsel, Palo Alto
Robert Eisenbach
Of Counsel, San Francisco
Robert Eisenbach
Of Counsel, San Francisco
Natasha Leskovsek
Of Counsel, Washington, DC
Elizabeth Caruso
Associate, New York
Eerik Kukebal
Associate, London
Amanda Pacheco
Associate, Palo Alto
Leo Spicer-Phelps
Associate, London
Lunga Su
Associate, Shanghai
Ivy Wang
Associate, Shanghai
Zhijing Yu
Associate, Singapore
Letian Wei
Legal Consultant, Shanghai

Related Practices & Industries

Longboard Pharmaceuticals Announces $2.6 Billion Sale to Lundbeck

October 14, 2024

Cooley advised Longboard Pharmaceuticals, a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, on its $2.6 billion sale to Lundbeck.

Read more

Related contacts

Kevin Cooper
Partner, New York
Steve Przesmicki
Partner, San Diego
Alessandra Murata
Partner, Palo Alto
David Burns
Special Counsel, Washington, DC
Jenny Ge
Associate, Santa Monica
Cristina Lombardi
Associate, New York
Jeewon Lee
Associate, New York
Charity Williams
Partner, San Diego
Son Nguyen
Special Counsel, Washington, DC
Stella Sarma
Special Counsel, Brussels
Ajay Athavale
Associate, San Francisco
Cara Buchicchio
Associate, New York
Elizabeth Caruso
Associate, New York
Jameson Davis
Associate, Boston
Sela Dougherty
Associate, New York
Rubin Waranch
Associate, Colorado

Related Practices & Industries

Personalis Announces Expanded Collaboration With Tempus AI

August 16, 2024

Cooley advised Personalis, a company transforming the active management of cancer through breakthrough personalized testing, on its expanded commercial relationship with Tempus AI, including an equity investment by Tempus into Personalis.

Read more

Related contacts

Bill Roegge
Partner, New York
Laura Berezin
Partner, Seattle
Asa Henin
Special Counsel, San Diego
Patrick Pang
Associate, New York
Allison Peth
Associate, Palo Alto
Jeewon Lee
Associate, New York
Matthew Choy
Associate, New York
Megan Browdie
Partner, Washington, DC
David Burns
Special Counsel, Washington, DC
Richard G.S. Lee
Associate, Washington, DC

Related Practices & Industries

Foreseen Biotechnology Announces Exclusive Global Licensing Agreement With Ipsen

July 11, 2024

Cooley advised Foreseen Biotechnology – an emerging biotech company that pioneered a high-throughput integrated translational proteomics platform powered by an artificial intelligence-based data analytical system to accelerate the discovery of novel targets for therapeutics and diagnostics that are clinically relevant – on its exclusive global licensing agreement with Ipsen for FS001, an antibody-drug conjugate with first-in-class potential.

Read more

Related contacts

Lila Hope
Partner, Palo Alto
Jennifer Raab
Partner, Palo Alto
Jiqiang Lin
Associate, New York
Robert Eisenbach
Of Counsel, San Francisco
Amanda Pacheco
Associate, Palo Alto
Xander Lee
Partner, Santa Monica
David Burns
Special Counsel, Washington, DC

Related Practices & Industries

View more

Admissions and credentials

District of Columbia

Virginia

Rankings and accolades

Super Lawyers Rising Stars: Antitrust (2018-2022)

Best Lawyers: Antitrust Law, Ones to Watch

Legal 500: Merger Control (2021)

Memberships and affiliations

American Bar Association (ABA)